Dual Incretin Receptor Agonists: How Far Have We Gone with “Twincretins"?
In this medfyle
Dual incretin receptor agonists are changing the goals of therapy for type 2 diabetes and weight loss.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This is a highlights summary of an oral session given at the ENDO 2022 Annual Conference and presented by:
Julio Rosenstock, MD
Dallas Diabetes Research Center at Medical City
University of Texas Southwestern Medical Center
Dallas, TX, USA
The content is produced by Infomedica, the official reporting partner of ENDO 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Vivian Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center